M. Cives, J. Strosberg (2014) An update on gastroenteropancreatic neuroendocrine tumors. Oncology (Williston Park, N.Y.) 28, 749–56, 758

M. Cives, J.R. Strosberg, Gastroenteropancreatic Neuroendocrine Tumors. CA Cancer J. Clin. (2018). https://doi.org/10.3322/caac.21493

Article  PubMed  Google Scholar 

S. Das, A. Dasari, Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences? Curr. Oncol. Rep. (2021). https://doi.org/10.1007/s11912-021-01029-7

Article  PubMed  PubMed Central  Google Scholar 

I.M. Modlin, K. Oberg, D.C. Chung, R.T. Jensen, W.W. de Herder, R.V. Thakker, M. Caplin, G. DelleFave, G.A. Kaltsas, E.P. Krenning, S.F. Moss, O. Nilsson, G. Rindi, R. Salazar, P. Ruszniewski, A. Sundin, Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. (2008). https://doi.org/10.1016/S1470-2045(07)70410-2

Article  PubMed  Google Scholar 

Y. Du, M. Ter-Minassian, L. Brais, N. Brooks, A. Waldron, J.A. Chan, X. Lin, P. Kraft, D.C. Christiani, M.H. Kulke, Genetic associations with neuroendocrine tumor risk: results from a genome-wide association study. Endocr. Relat. Cancer (2016). https://doi.org/10.1530/ERC-16-0171

Article  PubMed  PubMed Central  Google Scholar 

A. Di Domenico, T. Wiedmer, I. Marinoni, A. Perren, Genetic and epigenetic drivers of neuroendocrine tumours (NET). Endocr. Relat. Cancer (2017). https://doi.org/10.1530/ERC-17-0012

Article  PubMed  Google Scholar 

Finnerty BM, Gray KD, Moore MD, Zarnegar R, Fahey TJ III (2017) Epigenetics of gastroenteropancreatic neuroendocrine tumors: A clinicopathologic perspective. World J. Gastrointest. Oncol.https://doi.org/10.4251/wjgo.v9.i9.341

K. Kawasaki, K. Toshimitsu, M. Matano, M. Fujita, M. Fujii, K. Togasaki, T. Ebisudani, M. Shimokawa, A. Takano, S. Takahashi, Y. Ohta, K. Nanki, R. Igarashi, K. Ishimaru, H. Ishida, Y. Sukawa, S. Sugimoto, Y. Saito, K. Maejima, S. Sasagawa, H. Lee, H.-G. Kim, K. Ha, J. Hamamoto, K. Fukunaga, A. Maekawa, M. Tanabe, S. Ishihara, Y. Hamamoto, H. Yasuda, S. Sekine, A. Kudo, Y. Kitagawa, T. Kanai, H. Nakagawa, T. Sato, An Organoid Biobank of Neuroendocrine Neoplasms Enables Genotype-Phenotype Mapping. Cell (2020). https://doi.org/10.1016/j.cell.2020.10.023

Article  PubMed  Google Scholar 

A. Busico, P. Maisonneuve, N. Prinzi, S. Pusceddu, G. Centonze, G. Garzone, A. Pellegrinelli, L. Giacomelli, A. Mangogna, C. Paolino, A. Belfiore, K. Kankava, F. Perrone, E. Tamborini, G. Pruneri, N. Fazio, M. Milione, Gastroenteropancreatic high-grade neuroendocrine neoplasms: Histology and molecular analysis, two sides of the same coin. Neuroendocrinology (2020). https://doi.org/10.1159/000503722

Article  PubMed  Google Scholar 

C. Borga, G. Businello, S. Murgioni, F. Bergamo, C. Martini, E. de Carlo, E. Trevellin, R. Vettor, M. Fassan, Treatment personalization in gastrointestinal neuroendocrine tumors. Curr. Treat. Options Oncol. (2021). https://doi.org/10.1007/s11864-021-00825-4

Article  PubMed  Google Scholar 

Zeitschrift fur Gastroenterologie (2018) S2k-Leitlinie Neuroendokrine Tumore. https://doi.org/10.1055/a-0604-2924

S. Wullschleger, R. Loewith, M.N. Hall, TOR signaling in growth and metabolism. Cell (2006). https://doi.org/10.1016/j.cell.2006.01.016

Article  PubMed  Google Scholar 

J. Chan, M. Kulke, Targeting the mTOR signaling pathway in neuroendocrine tumors. Curr. Treat. Options Oncol. (2014). https://doi.org/10.1007/s11864-014-0294-4

Article  PubMed  PubMed Central  Google Scholar 

J.C. Yao, C. Lombard-Bohas, E. Baudin, L.K. Kvols, P. Rougier, P. Ruszniewski, S. Hoosen, J. St Peter, T. Haas, D. Lebwohl, E. van Cutsem, M.H. Kulke, T.J. Hobday, T.M. O’Dorisio, M.H. Shah, G. Cadiot, G. Luppi, J.A. Posey, B. Wiedenmann, Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J. Clin. Oncol. (2010). https://doi.org/10.1200/JCO.2009.24.2669

Article  PubMed  PubMed Central  Google Scholar 

L.B. Anthony, M.E. Pavel, J.D. Hainsworth, L.K. Kvols, S. Segal, D. Hörsch, E. van Cutsem, K. Öberg, J.C. Yao, Impact of previous somatostatin analogue use on the activity of everolimus in patients with advanced neuroendocrine tumors: Analysis from the phase III RADIANT-2 trial. Neuroendocrinology (2015). https://doi.org/10.1159/000381715

Article  PubMed  Google Scholar 

J.C. Yao, M. Pavel, C. Lombard-Bohas, E. van Cutsem, M. Voi, U. Brandt, W. He, D. Chen, J. Capdevila, E.G.E. de Vries, P. Tomassetti, T. Hobday, R. Pommier, K. Öberg, Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: Overall survival and circulating biomarkers from the randomized, phase III RADIANT-3 study. J. Clin. Oncol. (2016). https://doi.org/10.1200/JCO.2016.68.0702

Article  PubMed  PubMed Central  Google Scholar 

N. Fazio, R. Buzzoni, G. DelleFave, M.E. Tesselaar, E. Wolin, E. van Cutsem, P. Tomassetti, J. Strosberg, M. Voi, L. Bubuteishvili-Pacaud, A. Ridolfi, F. Herbst, J. Tomasek, S. Singh, M. Pavel, M.H. Kulke, J.W. Valle, J.C. Yao, Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis. Cancer Sci. (2018). https://doi.org/10.1111/cas.13427

Article  PubMed  Google Scholar 

C. Sciammarella, A. Luce, F. Riccardi, C. Mocerino, R. Modica, M. Berretta, G. Misso, A.M. Cossu, A. Colao, G. Vitale, A. Necas, J. Fedacko, M. Galdiero, P. Correale, A. Faggiano, M. Caraglia, A. Capasso, A. Grimaldi, Lanreotide Induces cytokine modulation in intestinal neuroendocrine tumors and overcomes resistance to everolimus. Front. Oncol. (2020). https://doi.org/10.3389/fonc.2020.01047

Article  PubMed  PubMed Central  Google Scholar 

J. Pozas, M. San Román, T. Alonso-Gordoa, M. Pozas, L. Caracuel, A. Carrato, J. Molina-Cerrillo, Targeting angiogenesis in pancreatic neuroendocrine tumors: resistance mechanisms. IJMS (2019). https://doi.org/10.3390/ijms20194949

Article  PubMed  PubMed Central  Google Scholar 

E. Raymond, L. Dahan, J.-L. Raoul, Y.-J. Bang, I. Borbath, C. Lombard-Bohas, J. Valle, P. Metrakos, D. Smith, A. Vinik, J.-S. Chen, D. Hörsch, P. Hammel, B. Wiedenmann, E. van Cutsem, S. Patyna, D.R. Lu, C. Blanckmeister, R. Chao, P. Ruszniewski, Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. (2011). https://doi.org/10.1056/NEJMoa1003825

Article  PubMed  Google Scholar 

A. Rinke, H.-H. Müller, C. Schade-Brittinger, K.-J. Klose, P. Barth, M. Wied, C. Mayer, B. Aminossadati, U.-F. Pape, M. Bläker, J. Harder, C. Arnold, T. Gress, R. Arnold, Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J. Clin. Oncol. (2009). https://doi.org/10.1200/JCO.2009.22.8510

Article  PubMed  Google Scholar 

M.E. Caplin, M. Pavel, J.B. Ćwikła, A.T. Phan, M. Raderer, E. Sedláčková, G. Cadiot, E.M. Wolin, J. Capdevila, L. Wall, G. Rindi, A. Langley, S. Martinez, J. Blumberg, P. Ruszniewski, Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N. Engl. J. Med. (2014). https://doi.org/10.1056/NEJMoa1316158

Article  PubMed  Google Scholar 

L.K. Kvols, C.G. Moertel, M.J. O’Connell, A.J. Schutt, J. Rubin, R.G. Hahn, Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N. Engl. J. Med. (1986). https://doi.org/10.1056/NEJM198609113151102

Article  PubMed  Google Scholar 

J. Strosberg, G. El-Haddad, E. Wolin, A. Hendifar, J. Yao, B. Chasen, E. Mittra, P.L. Kunz, M.H. Kulke, H. Jacene, D. Bushnell, T.M. O’Dorisio, R.P. Baum, H.R. Kulkarni, M. Caplin, R. Lebtahi, T. Hobday, E. Delpassand, E. van Cutsem, A. Benson, R. Srirajaskanthan, M. Pavel, J. Mora, J. Berlin, E. Grande, N. Reed, E. Seregni, K. Öberg, M. Lopera Sierra, P. Santoro, T. Thevenet, J.L. Erion, P. Ruszniewski, D. Kwekkeboom, E. Krenning, Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N. Engl. J. Med. (2017). https://doi.org/10.1056/NEJMoa1607427

Article  PubMed  PubMed Central  Google Scholar 

J. Strosberg, E. Wolin, B. Chasen, M. Kulke, D. Bushnell, M. Caplin, R.P. Baum, P. Kunz, T. Hobday, A. Hendifar, K. Oberg, M.L. Sierra, T. Thevenet, I. Margalet, P. Ruszniewski, E. Krenning, Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated With 177Lu-Dotatate in the phase III NETTER-1 trial. J. Clin. Oncol. (2018). https://doi.org/10.1200/JCO.2018.78.5865

Article  PubMed  PubMed Central  Google Scholar 

H. Sorbye, E. Baudin, I. Borbath, M. Caplin, J. Chen, J.B. Cwikla, A. Frilling, A. Grossman, G. Kaltsas, A. Scarpa, S. Welin, R. Garcia-Carbonero, Unmet needs in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3). Neuroendocrinology (2019). https://doi.org/10.1159/000493318

Article  PubMed  Google Scholar 

D. Benten, Y. Behrang, L. Unrau, V. Weissmann, G. Wolters-Eisfeld, S. Burdak-Rothkamm, F.R. Stahl, M. Anlauf, P. Grabowski, M. Möbs, J. Dieckhoff, B. Sipos, M. Fahl, C. Eggers, D. Perez, M. Bockhorn, J.R. Izbicki, A.W. Lohse, J. Schrader, Establishment of the first well-differentiated human pancreatic neuroendocrine tumor model. Mol. Cancer Res. (2018). https://doi.org/10.1158/1541-7786.MCR-17-0163

Article  PubMed  Google Scholar 

H. Li, R. Durbin, Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics (2009). https://doi.org/10.1093/bioinformatics/btp324

Article  PubMed  PubMed Central  Google Scholar 

L.E. Mose, M.D. Wilkerson, D.N. Hayes, C.M. Perou, J.S. Parker, ABRA: improved coding indel detection via assembly-based realignment. Bioinformatics (2014). https://doi.org/10.1093/bioinformatics/btu376

Article  PubMed  PubMed Central  Google Scholar 

L. Bußmann, K. Hoffer, C.M. von Bargen, C. Droste, T. Lange, J. Kemmling, J. Schröder-Schwarz, A.T. Vu, L. Akingunsade, P. Nollau, S. Rangarajan, R. de Wijn, A. Oetting, C. Müller, L.C. Böckelmann, H.B. Zech, J.C. Berger, N. Möckelmann, C.-J. Busch, A. Böttcher, F. Gatzemeier, K. Klinghammer, D. Simnica, M. Binder, N. Struve, T. Rieckmann, U. Schumacher, T.S. Clauditz, C.S. Betz, C. Petersen, K. Rothkamm, A. Münscher, M. Kriegs, Analyzing tyrosine kinase activity in head and neck cancer by functional kinomics: Identification of hyperactivated Src family kinases as prognostic markers and potential targets. Int. J. Cancer (2021). https://doi.org/10.1002/ijc.33606

Article  PubMed  Google Scholar 

J. Schrader, T.T. Gordon-Walker, R.L. Aucott, M. van Deemter, A. Quaas, S. Walsh, D. Benten, S.J. Forbes, R.G. Wells, J.P. Iredale, Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells. Hepatology (2011). https://doi.org/10.1002/hep.24108

Article  PubMed  Google Scholar 

Y. Zhang, X. Wang, Targeting the Wnt/β-catenin signaling pathway in cancer. J. Hematol. Oncol. (2020). https://doi.org/10.1186/s13045-020-00990-3

Article  PubMed  PubMed Central  Google Scholar 

C. Wu, J. Lyu, E.J. Yang, Y. Liu, B. Zhang, J.S. Shim, Targeting AURKA-CDC25C axis to induce synthetic lethality in ARID1A-deficient colorectal cancer cells. Nat. Commun. (2018). https://doi.org/10.1038/s41467-018-05694-4

Article  PubMed  PubMed Central  Google Scholar 

C.T. Williamson, R. Miller, H.N. Pemberton, S.E. Jones, J. Campbell, A. Konde, N. Badham, R. Rafiq, R. Brough, A. Gulati, C.J. Ryan, J. Francis, P.B. Vermulen, A.R. Reynolds, P.M. Reaper, J.R. Pollard, A. Ashworth, C.J. Lord, ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A. Nat. Commun. (2016). https://doi.org/10.1038/ncomms13837

Article  PubMed  PubMed Central  Google Scholar 

R.L. Flynn, K.E. Cox, M. Jeitany, H. Wakimoto, A.R. Bryll, N.J. Ganem, F. Bersani, J.R. Pineda, M.L. Suvà, C.H. Benes, D.A. Haber, F.D. Boussin, L. Zou, Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Sci. (New York, N.Y.) (2015). https://doi.org/10.1126/science.1257216